JNCE

Jounce Therapeutics, Inc. (JNCE) | Rumor.io

Jounce Therapeutics

JNCE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about JNCE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

May 5

Jounce Therapeutics, Inc. ($JNCE) has received a tender offer and schedule 14D-9 notice, with an expiration date of May 3.
Concentra Biosciences, LLC, a 10% owner of Jounce Therapeutics, has acquired 10,000 shares of common stock at $9,737.7 per share on May 4.
Jounce Therapeutics has announced the closing of its tender offer, and a director, Kevin C. Tang, has disposed of 5,300,087 shares and acquired 10,000 shares at $1.85 per share.

Generated by AI

Sentiment

Of the messages about JNCE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	0% -100
Bearish	—	—	—	100% new

Bullish· Mar 27

$JNCE has seen a significant price increase, with one post noting a 96% return and another post stating the price is up 24.32% since an alert was sent.
The Concentra buyout of $JNCE is expected to be worth more than the current price, suggesting that the asset has untapped value.
Tang Capital's increased holding in $JNCE and its history of making acquisition offers, such as its bid for $BMS, has driven price increases in the past and is expected to do so again.

Bearish· Mar 15

$JNCE is experiencing a significant drop, with some investors attributing it to a potential pump and dump scheme.
The company's recent business combination with Redx Pharma may be contributing to its decline, with some shareholders expressing skepticism about the deal.
$JNCE's price is being artificially suppressed, with some investors suggesting that institutions are dumping shares at this price, leading to a potential return to $1.10.

Generated by AI

Topics

Of the messages about JNCE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· Aug 9

Jounce Therapeutics ($JNCE) beats earnings estimates by $0.23.
The company reports a beat on revenue.
Earnings results are released, with a reported EPS of $0.14.

Analysts· Jun 4

Jounce Therapeutics' ($JNCE) stock was downgraded to Neutral from Overweight at JPMorgan Chase, with a new price target of $12.
JPMorgan Chase cut its price target for Jounce Therapeutics to $12 from $28, while Robert W. Baird reiterated a Buy rating with a target price of $20.
Analysts at Baird and Wells Fargo reaffirmed their ratings for Jounce Therapeutics, with Baird keeping an Outperform rating and a target price of $20, and Wells Fargo maintaining a Market Perform rating with a target price of $10.

Announcements· Mar 27

Jounce Therapeutics, Inc. (JNCE) has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right.
Jounce Therapeutics has implemented a workforce reduction of approximately 84% of its employees, expected to be completed within the next month.
Jounce Therapeutics has halted trading amid news of an acquisition proposal, with trading to resume at 09:50:00 ET on NASDAQ on March 27, 2023.

Technical Analysis· Mar 15

$JNCE is setting up for a potential cross, with a possible push into the $1.52 level.
The stock has a demand zone of $1.35-$1.45, a supply zone of $1.50-$1.60, and an exhaustion level of $1.34.
$JNCE has strong resistance between $1.38 and $1.55, and needs to clear this level for a big move.

Generated by AI

Community

Of the messages about JNCE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Regulars· May 4

Jounce Therapeutics has been acquired by Concentra Biosciences, with the acquisition being completed on May 4th.
The acquisition led to a trading halt, with NASDAQ requesting additional information on May 3rd.
Jounce Therapeutics has closed its tender offer, with the company notifying NASDAQ of the consummation of the merger on May 4th.

Newcomers· Mar 27

Jounce Therapeutics, Inc. is implementing a workforce reduction of approximately 84% of its employees, with the reduction expected to be completed within the next month.
The company has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right.
The acquisition has been halted, with trading pending, and Jounce Therapeutics has agreed to be acquired by Concentra Biosciences for $1.85 per share.

Generated by AI

Also Discussed

Investors talking about JNCE also mention

#	Name	Attention
1	BLCM - Bellicum Pharmaceuticals, Inc.	——
2	AnaptysBio, Inc.ANAB	0%0
3	Karyopharm Therapeutics Inc.KPTI	0%new
4	MYOV - Myovant Sciences Ltd.	——
5	Palvella Therapeutics IncPIRS	0%0
6	Minerva Surgical Inc.UTRS	0%0
7	FUSN - Fusion Pharmaceuticals Inc.	——
8	Paysign Inc.PAYS	0%new
9	Bicycle Therapeutics plc - ADRBCYC	0%0
10	ISO - IsoPlexis Corporation	——